Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 5/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | TDP2 | O95551 | 1/20 | 0.38 |
| ▸ | NSD2 | O96028 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | GALK1 | P51570 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5352485 | 0.79 | MAPT (0.41) | CYP3A4TSHRALDH1A1HPGDHSD17B10 | |
| SCHEMBL5894127 | 0.78 | HSP90AA1 (0.36) | CYP3A4TSHRALDH1A1HPGDHSD17B10 | |
| SCHEMBL29126971 | 0.77 | MAPT (0.42) | CYP3A4TSHRALDH1A1HPGDHSD17B10 | |
| SCHEMBL5894441 | 0.76 | ALDH1A1 (0.40) | CYP3A4TSHRALDH1A1HPGDHSD17B10 | |
| SCHEMBL2133978 | 0.74 | CYP2A6 (0.43) | TSHRALDH1A1HPGDHSD17B10TDP1 | |
| SCHEMBL21530568 | 0.74 | MAPT (0.38) | TDP1KDM4EMAPTKMT2ATDP2 | |
| SCHEMBL34468885 | 0.74 | MAPT (0.43) | CYP3A4TSHRALDH1A1HPGDHSD17B10 | |
| SCHEMBL3137043 | 0.74 | CYP2A6 (0.43) | TSHRTDP1KDM4EMAPTKMT2A | |
| SCHEMBL100824 | 0.74 | MAPT (0.43) | CYP3A4TSHRALDH1A1HPGDHSD17B10 | |
| SCHEMBL6684284 | 0.73 | ALDH1A1 (0.50) | TSHRALDH1A1HPGDHSD17B10TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111058069-A | Plating solution for electroplating tin alloy | 上村工业株式会社 | 2020-04-24 | — | — | CN | claimed |
| US-20200123673-A1 | ELECTROLYTIC TIN ALLOY PLATING SOLUTION | C. UYEMURA & CO., LTD. (JP) | 2020-04-23 | — | — | US | claimed |
| US-20250099488-A1 | ANTI-PARASITE COMPOUNDS | AUSTRALIAN NATIONAL UNIVERSITY (AU) | 2025-03-27 | — | — | US | disclosed |
| EP-4469058-A1 | ANTI-PARASITE COMPOUNDS | Australian National University (AU) | 2024-12-04 | — | — | EP | disclosed |
| WO-2023137529-A1 | ANTI-PARASITE COMPOUNDS | AUSTRALIAN NATIONAL UNIVERSITY (AU) | 2023-07-27 | — | — | WO | disclosed |
| US-20230128322-A1 | SYK KINASE INHIBITORS AS TREATMENT FOR MALARIA | PURDUE RESEARCH FOUNDATION | 2023-04-27 | — | — | US | disclosed |
| US-20200345737-A1 | SYK KINASE INHIBITORS AS TREATMENT FOR MALARIA | PURDUE RESEARCH FOUNDATION | 2020-11-05 | — | — | US | disclosed |
| WO-2020107189-A1 | PYRROLIDINE COMPOUNDS FOR THE TREATMENT OF MALARIA | LEGION PHARMA CO. LTD (CN) | 2020-06-04 | — | — | WO | disclosed |
| CN-111058069-A | Plating solution for electroplating tin alloy | 上村工业株式会社 | 2020-04-24 | — | — | CN | disclosed |
| US-20200123673-A1 | ELECTROLYTIC TIN ALLOY PLATING SOLUTION | C. UYEMURA & CO., LTD. (JP) | 2020-04-23 | — | — | US | disclosed |
| US-9701637-B2 | Tau imaging probe | GE HEALTHCARE LIMITED (GB) | 2017-07-11 | — | — | US | disclosed |
| US-20140309233-A1 | SYK KINASE INHIBITORS AS TREATMENT FOR MALARIA | HULOW, LLC (US) | 2014-10-16 | — | — | US | disclosed |
| US-20140296532-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MALARIA | GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCES (CN) | 2014-10-02 | — | — | US | disclosed |
| WO-2014160775-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MALARIA | SAINT LOUIS UNIVERSITY (US) | 2014-10-02 | — | — | WO | disclosed |
| WO-2014100113-A2 | SYK KINASE INHIBITORS AS TREATMENT FOR MALARIA | HULOW, LLC (US) | 2014-06-26 | — | — | WO | disclosed |
| US-20140100178-A1 | COMPOSITION AND METHODS FOR SITE-SPECIFIC DRUG DELIVERY TO TREAT MALARIA AND OTHER LIVER DISEASES | ANSARI ASLAM (US) | 2014-04-10 | — | — | US | disclosed |
| EP-2188259-B1 | QUINOLINE DERIVATIVES AS ANTI-CANCER AGENTS | UNIV HONG KONG POLYTECHNIC (CN) | 2013-11-06 | — | — | EP | disclosed |
| EP-2634177-A1 | TAU IMAGING PROBE | Clino Ltd. (JP) | 2013-09-04 | — | — | EP | disclosed |
| US-20090054482-A1 | Method of making and administering quinoline derivatives as anti-cancer agents | THE HONG KONG POLYTECHNIC UNIVERSITY (HK) | 2009-02-26 | — | — | US | disclosed |
| US-5837289-A | ORGANOGEL COMPRISING FATTY ACID PHOSPHOLIPID EMULSIFYING AGENT AND FATTY ACID OR ESTER THEREOF | IMPRIMIS PHARMACEUTICALS, INC. | 1998-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230128322-A1 | SYK KINASE INHIBITORS AS TREATMENT FOR MALARIA | SYK, BTK, MERTK | CYP3A4 4082/4885TSHR 4179/4885ALDH1A1 4131/4885 |
| US-20250099488-A1 | ANTI-PARASITE COMPOUNDS | TUBA3C, CFAP20, CFAP410 | CYP3A4 3433/4885TSHR 4563/4885ALDH1A1 1357/4885 |
| US-20140309233-A1 | SYK KINASE INHIBITORS AS TREATMENT FOR MALARIA | SYK, BTK, MERTK | CYP3A4 4082/4885TSHR 4179/4885ALDH1A1 4131/4885 |
| US-20140100178-A1 | COMPOSITION AND METHODS FOR SITE-SPECIFIC DRUG DELIVERY TO TREAT MALARIA AND OTHER LIVER DISEASES | HEXD, LCT, PYGL | CYP3A4 256/4885TSHR 3769/4885ALDH1A1 457/4885 |
| US-20140296532-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MALARIA | BACE2, DNPEP, ACE | CYP3A4 749/4885TSHR 4876/4885ALDH1A1 1822/4885 |
| US-20090054482-A1 | Method of making and administering quinoline derivatives as anti-cancer agents | HCCS, GLS2, NQO1 | CYP3A4 172/4885TSHR 4295/4885ALDH1A1 959/4885 |
| US-20200345737-A1 | SYK KINASE INHIBITORS AS TREATMENT FOR MALARIA | SYK, BTK, MERTK | CYP3A4 4082/4885TSHR 4179/4885ALDH1A1 4131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.